Working Toward a Solution
At Astante Therapeutics we develop drugs with novel mechanisms of action that are enhanced by drug efflux. Our unique drug delivery strategy co-opts drug efflux for therapeutic benefit by linking an anti-cancer immune response, from bystander immune cells, to drug efflux in MDR cancers. We call this platform, where anti-cancer efficacy is induced from bystander immune cells (such as tumor infiltrating lymphocytes), Bystander-Assisted ImmunoTherapy, or BAIT.
We envision BAIT will be a new class of therapy that is effective against MDR cancers, and may even be capable of re-sensitizing MDR cancers toward more traditional chemotherapeutics.